AI / ML INNOVATIONS INC - AIMLF STOCK NEWS

AI/ML Innovations Inc. has entered into a Debt Settlement and Security Agreement with ThreeD Capital Inc. for a debt of $47,460 related to services provided. The debt will be settled through the issuance of 949,200 common shares at a price of $0.05 per share. This transaction is subject to approval by the Canadian Securities Exchange (CSE) and the shares will be restricted for a four-month period.

AI/ML Innovations focuses on investments in artificial intelligence (AI) and machine learning (ML) within the digital health sector. Their strategic partnerships include a 95.2% stake in Health Gauge, 12.44% ownership in Tech2Heal (right to increase up to 22%), and a 70% stake in AI Rx Inc.

The company's shares trade on the Canadian Securities Exchange under the symbol AIML, on the OTCQB under AIMLF, and on the Frankfurt Stock Exchange under 42FB.

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) has announced a proposed non-brokered private placement of up to 6,000,000 units at $0.05 per unit, aiming to raise up to $300,000. Each unit consists of one common share and one warrant, exercisable at $0.10 per share for two years. The company plans to use the net proceeds for working capital requirements. The private placement is subject to regulatory approvals, including from the Canadian Securities Exchange. AI/ML Innovations focuses on artificial intelligence and machine learning in the digital health and wellbeing sector, with investments in Health Gauge, Tech2Heal, and AI Rx Inc.

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) has completed its non-brokered private placement on July 17, 2024. The company raised a total of $971,500 by issuing 19,430,000 units at $0.05 per unit. Each unit consists of one common share and one warrant, exercisable at $0.10 for three years. The final tranche raised $511,500 from 10,230,000 units. AI/ML paid $26,477.60 in finder's fees and issued 529,550 broker warrants. The securities are subject to a hold period until November 18, 2024. The company plans to use the net proceeds for working capital requirements.

AI/ML Innovations, a leader in AI and machine learning solutions, announces a live webinar event on July 11th at 9:00 AM PT / 12:00 PM ET. Paul Duffy, CEO, will recap the past 90 days, discuss upcoming 90 days, and outline key Q3 milestones. The company focuses on AI and ML investments in digital health and well-being, with significant stakes in Health Gauge, Tech2Heal, and AI Rx Inc. Shares are traded under CSE: AIML, OTCQB: AIMLF, and FWB: 42FB.

AI/ML Innovations has completed the first closing of its non-brokered private placement, raising $460,000 out of a potential $850,000. The company issued 9.2 million units at $0.05 per unit. Each unit includes one common share and one warrant, exercisable at $0.10 per share within three years. If shares trade at $0.25 for ten days, the company can accelerate the warrant expiry with 30 days' notice. A statutory hold period applies until November 2, 2024. Finder's fees totaled $29,850, with 417,000 broker warrants issued. The funds will support working capital.

AI/ML Innovations announced a non-brokered private placement offering up to 16,500,000 units at $0.05 per unit to raise up to $850,000. Each unit includes one common share and one warrant. Warrants are exercisable into common shares at $0.10 per share within three years, with a potential acceleration clause. The funds are intended for working capital. The placement is subject to Canadian Securities Exchange approval and includes a finder's fee. AI/ML Innovations focuses on AI and ML in digital health, holding significant stakes in Health Gauge, Tech2Heal, and AI Rx Inc.

AI/ML Innovations (CSE:AIML, OTCQB:AIMLF, FWB:42FB) has launched TheNeuralCloud.com through its subsidiary NeuralCloud Solutions. This Neural Net as a Service (NNaaS) platform offers healthcare providers, device developers, and researchers access to advanced neural networks for analyzing cloud-based biometric data. The platform's first service is a proprietary ECG Neural Net, capable of detailed beat-to-beat labeling for ECGs up to 48 hours, covering around 170,000 heartbeats. This enhancement aims to provide critical insights into cardiovascular health and other conditions, potentially improving healthcare outcomes. CEO Paul Duffy expressed excitement over this subscription-based service, which offers unparalleled access to neural network technologies.

AI/ML Innovations Inc. (AIML) has finalized the acquisition of cutting-edge technology from Naiad Lab, a deal completed on June 3, 2024. The acquisition includes Naiad's proprietary Long ECG Neural Net (L-ECG NN) for detailed cardiovascular insights and the Neural Network Store (NNStore), a subscription-based AI analysis platform.

Key aspects of the acquisition include AIML issuing 6.7 million common shares valued at $335,000 to Naiad and creating a new subsidiary to manage the assets. Additionally, AIML will pay a royalty to Naiad based on revenue generated from the L-ECG NN technology and has granted 700,000 stock options to Naiad's management. The deal involves contingent shares that convert to common shares if certain milestones are met, including FDA approval and revenue targets.

This strategic acquisition aims to enhance AIML's portfolio and position it at the forefront of AI-driven healthcare innovations.

AI/ML Innovations has launched The Neural Net Store, an online commercial portal offering flexible, affordable access to its AI-driven healthcare solutions. The NNStore features products like the Follow Your Heart suite for Blood Pressure measurement and a Long ECG Neural Network analytical tool. Users can access these tools via downloadable APIs for integration into third-party applications or through a cloud-based Neural Net Service (NNaaS). This service is designed to eliminate barriers in adopting AI solutions in healthcare, offering options for both infrequent and frequent users, including developers and healthcare organizations. The introduction of the NNStore aims to facilitate easier implementation of AI technologies, thereby driving innovation in healthcare.